Drug Profile
Research programme: skin disorder therapeutics
Latest Information Update: 02 Aug 2017
Price :
$50
*
At a glance
- Originator Pfizer
- Class
- Mechanism of Action Stearoyl CoA desaturase inhibitors; Transforming growth factor beta1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acne; Scars
Most Recent Events
- 27 Jul 2017 Valeant Pharmaceuticals International acquired Ortho Dermatologics in 2011 and changed the name of the later to Valeant Dermatology. Subsequently, in July 2017, it was rebranded to Ortho Dermatologics
- 02 Dec 2011 Medicis Pharmaceutical Corporation acquires pharmaceuticals assets of Graceway Pharmaceuticals
- 02 Dec 2011 No development reported - Preclinical for Scars in USA (unspecified route)